New uses for old drugs: neonatal diabetes and sulphonylureas.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 20197050.
- Also identified by DOI 10.1016/j.cmet.2010.02.004.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The discovery that their neonatal diabetes is caused by gain-of-function mutations in the K(ATP) channel has enabled many patients to switch from insulin to oral sulphonylurea drugs. Here, I review molecular, physiological, and clinical features of this change in therapy.
Medical subject headings
- Diabetes Mellitus
- KATP Channels
- Mutation
- Sulfonylurea Compounds